Table 2:
Patients characteristics of the YSM cohort.
| (n = 104) | |
|---|---|
| Clinical characteristics | |
| Sex, n (%) | |
| Male | 51 (49.0) |
| Female | 53 (51.0) |
| Age | |
| Median, n (range) | 61 (25–86) |
| Location of tumor, n (%) | |
| Trunk | N/A |
| Extremity | N/A |
| T-stage, n (%) | |
| T1a or T1b | 23 (22.1) |
| T2a | 13 (12.5) |
| T2b or T3a | 30 (28.9) |
| T3b or T4a | 22 (21.2) |
| T4b | 14 (13.5) |
| Unknown | 2 (1.9) |
| Stage, n(%) | |
| I | N/A |
| II | N/A |
| III | N/A |
| Pathologic characteristics | |
| Depth (mm) | |
| Median, n (range) | 2.35 (0.15–8.30) |
| Ulceration, n (%) | |
| Absent | 63 (60.6) |
| Present | 39 (37.5) |
| Unknown | 2 (1.9) |
| Microsatellite lesions, n (%) | |
| Absent | 76 (73.1) |
| Present | 26 (25.0) |
| Unknown | 2 (1.9) |
| TILs | |
| Absent | 6 (5.8) |
| Non-brisk | 77 (74.0) |
| Brisk | 19 (18.3) |
| Unknown | 2 (1.9) |
| SLNB status, n (%) | |
| Completed | N/A |
| Positive, n (% of completed) | N/A |
| Negative, n (% of completed) | N/A |
| Not completed | N/A |
| Outcome characteristics | |
| Patient follow-up (months) | |
| Median, n (range) | 68.7 (1.4–456.2) |
| DMR, n (%) | |
| Distant recurrence | 46 (44.2) |
| No distant recurrence or local recurrence only | 58 (55.8) |
| OS, n (%) | |
| Alive (at least 2 years) | 26 (25.0) |
| Dead | 78 (75.0) |
| DSS, n (%) | |
| Alive or NED at death | 58 (55.8) |
| Median follow-up (months) | 114.4 |
| Dead with melanoma | 46 (44.2) |
| Median follow-up (months) | 36.7 |
| Unknown | 0 (0) |
Abbreviations: DMR, distant metastatic recurrence; DSS, disease-specific survival; NED, no evidence of disease; OS, overall survival